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Gap junctions and 
renin secretion
Renin is secreted by cells that are coupled 
to each other and to endothelial cells 
by gap junctions. The major protein of 
these junctions is connexin40 (Cx40). 
As they report in this issue, Krattinger 
et al. found that Cx40 knockout mice 
were hypertensive because of an increase 
in the number of renin-secreting cells 
and, consequently, higher plasma renin. 
Blockade of the renin–angiotensin 
system lowered blood pressure in the 
knockout mice to the same levels as 
those of wild-type mice. Hypertension 
was not aﬀected by a high-salt diet or 
by clipping of the renal artery. Under 
these conditions, however, Cx40–/– mice 
showed altered production and release of 
renin. The renin-secreting cells did not 
overexpress other gap junction proteins 
such as Cx43 or Cx37. The mechanism by 
which renin secretion and biosynthesis 
is dependent on the coupling between 
renin-secreting cells remains unknown 
but is likely to be a fruitful area of future 
study. See page 814.





Cytotoxic CD8 cells are implicated 
in the generation of many immune-
mediated diseases, including 
glomerulonephritis. These cells secrete 
many toxic molecules, of which 
granzyme/perforin are an important 
class. Using a model of crescentic 
glomerulonephritis in rats, Fujinaka 
et al. discovered that the glomeruli 
of these animals had a proportional 
increase in CD8 cells and perforin 
mRNA. They did not ﬁnd an increase 
of Fas ligand, another toxin that the 
lymphocyte produces. When CD8 
cells were depleted, the granzyme 
from their glomeruli was depleted as 
well. When animals were treated with 
neutralizing antibodies to perforin 
in vivo, they had less proteinuria and 
fewer crescentic glomeruli, although 
the number of inﬁltrating CD8 cells 
did not change. If these ﬁndings are 
repeated in clinical studies, they may 
provide a new therapeutic avenue 
for the treatment of aggressive 




Microalbuminuria is an independent 
risk factor for cardiovascular disease 
in hypertensive patients, especially 
in those with concomitant diabetes 
or established cardiovascular disease. 
In a randomized controlled study, 
Bakris et al. treated hypertensive 
patients with microalbuminuria 
and increased cardiovascular risk 
with an angiotensin-converting 
enzyme inhibitor with or without 
an angiotensin receptor blocker. The 
primary end point was a change in 
albumin excretion rate. There was 
no diﬀerence between the single-
treatment group and the group treated 
with both drugs regarding progression 
of albuminuria. Although diﬀerences 
in blood pressure reduction were 
observed between the two treatment 
groups, these changes did not aﬀect 
microalbuminuria. Although more 
patients on dual therapy achieved 
target blood pressure goals, the 
incidence of adverse eﬀects was similar 
in both groups. The treatment protocol 
lasted 20 weeks and may have been 
too short to demonstrate diﬀerences in 
risk.  See page 879.
